Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

Part of paid clinical trials in Tucson, Arizona.

Sponsor
SWOG Cancer Research Network
Study ID
NCT07062354
Phase
PHASE2
Status
Enrolling By Invitation

Conditions

  • Head &Amp; Neck Cancer
  • Head &Amp; Neck Squamous Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This research study is for people who have head and neck cancer that has come back or spread to other places in the body.

Key Dates

Start date
Mar 25, 2026
Status verified
May 2026
Primary completion
Oct 31, 2028
Completion
Oct 31, 2029

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Participants with unresectable recurrent or metastatic HNSCC
    Carboplatin + Paclitaxel + Amivantamab hyaluronidase

Primary Outcome Measure

Overall Response Rate [ Time Frame: Up to 2 years after registration ]

Locations (3)

FacilityCityStateZIPSite coordinators
University of Arizona Cancer CenterTucsonArizona85719-
University of Michigan Rogel Cancer CenterAnn ArborMichigan48109-
University of Nebraska Medical CenterOmahaNebraska68198-

Find similar trials in Tucson, AZ

By research site
University of Arizona Cancer Center· Tucson, AZUniversity of Michigan Rogel Cancer Center· Ann Arbor, MIUniversity of Nebraska Medical Center· Omaha, NE

Related Studies